<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Approach to managing increased risk for cardiovascular disease in patients with severe mental illness</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Approach to managing increased risk for cardiovascular disease in patients with severe mental illness</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Approach to managing increased risk for cardiovascular disease in patients with severe mental illness</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen Marder, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">L Fredrik Jarskog, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Benjamin Druss, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Murray B Stein, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael Friedman, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2113084620"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Lifespans in people with severe mental illness (SMI) are reduced by 15 to 25 years compared with the general population [<a href="#rid1">1-3</a>]. Cardiovascular disease (CVD) represents the most common natural cause of this excess mortality [<a href="#rid1">1,4,5</a>]. People with schizophrenia, for example, are twice as likely to die from CVD [<a href="#rid6">6-8</a>].</p><p>The elevated risk of CVD among patients with SMI is caused in part by the increased prevalence of CVD risk factors in this population – obesity, diabetes mellitus, hypertension, and dyslipidemia – compared with the general population. Other factors contributing to increased CVD in patients with SMI include a possible genetic predisposition, as well as behaviors such as smoking, lack of physical exercise, and poor diet leading to excess body weight.</p><p>Multiple, concurrent risk factors for CVD are described, collectively, as metabolic syndrome, which is more common in patients with SMI compared with the general population. Metabolic syndrome is also a common side effect of antipsychotic medications. Metabolic abnormalities, however, often go undiagnosed and untreated or undertreated in patients with SMI.</p><p>This topic reviews our approach to selecting treatments for CVD risk factors in patients with SMI  (<a class="graphic graphic_algorithm graphicRef118498" href="/z/d/graphic/118498.html" rel="external">algorithm 1</a>). The epidemiology, pathogenesis, and clinical implications of metabolic syndrome in patients with SMI are reviewed separately. The epidemiology, administration of treatments, treatment efficacy of CVD risk factors in patients with SMI and lifestyle interventions for obesity and overweight patients with SMI are also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/14775.html" rel="external">"Metabolic syndrome in patients with severe mental illness: Epidemiology, contributing factors, pathogenesis, and clinical implications"</a> and  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness"</a> and  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness"</a>.)</p><p class="headingAnchor" id="H4218286385"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Patients with severe mental illness (SMI) are at risk for cardiovascular disease (CVD) and should be routinely monitored for metabolic abnormalities and receive aggressive treatment when present. A recommended monitoring schedule is summarized in a table  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 1</a>) and reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Monitoring'</a>.)</p><p>The overall goal of treating metabolic abnormalities is to prevent the development of type 2 diabetes and CVD. All patients with SMI, regardless of whether they are taking an antipsychotic drug, should receive education about nutrition and weight management and encouragement to increase physical activity.</p><p>The selection of a treatment strategy for one or more metabolic abnormalities depends on multiple factors including the patient’s history of responsiveness to different antipsychotics, the severity of the metabolic disturbance, and the willingness of the patient to make lifestyle changes. Since there are often multiple contributors to CVD, treatment will often include both medical and lifestyle interventions.</p><p>Treatment for metabolic risk in patients with SMI is similar whether or not the patient takes an antipsychotic drug:</p><p class="bulletIndent1"><span class="glyph">●</span>For patients who acquire CVD risk factors as side effects of an antipsychotic medication, the choice and dose of antipsychotic should be reevaluated. (See <a class="local">'Patients taking an antipsychotic drug'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All overweight patients with SMI should receive education on weight management and encouragement to increase physical activity, preferably through a lifestyle intervention tailored to the needs of the individual patient. (See <a class="local">'Obesity and overweight patients'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other metabolic abnormalities and risk factors should be treated individually if they persist despite antipsychotic and lifestyle changes. (See <a class="local">'Other metabolic abnormalities'</a> below.)</p><p></p><p class="headingAnchor" id="H1938324601"><span class="h1">PATIENTS TAKING AN ANTIPSYCHOTIC DRUG</span><span class="headingEndMark"> — </span>For patients with antipsychotic-induced weight gain, we suggest reviewing the antipsychotic regimen for the feasibility of the options below (see  <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">"Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Implementation of medication changes'</a>):</p><p class="headingAnchor" id="H1448119106"><span class="h2">Antipsychotic dose reduction</span><span class="headingEndMark"> — </span>The patient’s medication history, clinical status, and current antipsychotic should be reviewed for opportunities to reduce the dose. Dose reduction should be done gradually and under close monitoring for the possibility of symptom exacerbation.</p><p class="headingAnchor" id="H3404235970"><span class="h2">Switching antipsychotic drugs</span><span class="headingEndMark"> — </span>Studies have shown that switching from an antipsychotic with a relatively high risk of weight gain and dyslipidemia (eg, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>) to an antipsychotic with lower risks (eg, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> or <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>) is often (but not always) effective in promoting weight loss and improving lipid profiles  (<a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">table 2</a>) [<a href="#rid9">9-11</a>].</p><p>Careful monitoring of clinical status is recommended when attempting such a switch. A gradual cross titration from the current to the newer drug over one to three weeks will usually protect patients against an exacerbation of psychosis. For some patients, however, the risks of exacerbation with switching may be unacceptably high, such as those stabilized on <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, or on an antipsychotic from which they have previously decompensated following an attempted switch to another drug.</p><p>Weight loss may not occur immediately; patients should be observed for at least two to three months to assess the effectiveness of the change.</p><p class="headingAnchor" id="H4142047246"><span class="h1">OBESITY AND OVERWEIGHT PATIENTS</span><span class="headingEndMark"> — </span>Patients with serious mental illness (SMI) are at increased risk for obesity compared with the general population. For patients with SMI who are overweight (body mass index between 25 and ≤30), we suggest first-line treatment with either a comprehensive lifestyle intervention or medication, with the choice based on the intervention’s availability as well as the patient’s preferences, motivation, and capabilities.</p><p>Compared with the general population, patients with SMI are more likely to have lifestyles placing them at increased risk of obesity, with less physical activity and unhealthier diets [<a href="#rid12">12-14</a>]. Lifestyle interventions developed to help overweight patients from the general population to lose weight can present challenges to patients with SMI. (See  <a class="medical medical_review" href="/z/d/html/5371.html" rel="external">"Obesity in adults: Overview of management", section on 'Comprehensive lifestyle intervention'</a> and  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness", section on 'Addressing challenges with SMI'</a>.)</p><p>For patients with the willingness and capability to participate, a lifestyle intervention should generally be recommended first, proceeding to medication if the intervention is ineffective. Data on weight gain among patients who have recently started taking an antipsychotic [<a href="#rid15">15</a>] support more aggressive management (ie, an earlier introduction of medication treatment).</p><p class="headingAnchor" id="H2006011181"><span class="h2">Preference for lifestyle intervention</span><span class="headingEndMark"> — </span>In our clinical experience, lifestyle interventions customized to challenges faced by patients with SMI can help them to lose weight and improve other metabolic abnormalities. Clinical trials of the interventions versus inactive controls (which are reviewed separately) have shown mixed results [<a href="#rid16">16</a>]. Their efficacy has not been compared with that of medication for weight loss, nor has the combination of lifestyle interventions and medication been compared with either as monotherapy. (See  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness", section on 'Efficacy'</a>.)</p><p>The availability of lifestyle interventions customized for SMI patients is limited, varying widely even in countries where they have been disseminated. (See  <a class="medical medical_review" href="/z/d/html/105454.html" rel="external">"Lifestyle interventions for obesity and overweight patients with severe mental illness", section on 'Key components'</a>.)</p><p>Based on data from intervention trials, we favor the use of interventions with characteristics associated with better outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>In SMI patients [<a href="#rid17">17</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Longer duration (three or more months)</p><p class="bulletIndent2"><span class="glyph">•</span>Manualized, structured approach</p><p class="bulletIndent2"><span class="glyph">•</span>Focus on both health education and physical activity</p><p class="bulletIndent2"><span class="glyph">•</span>Active monitoring such as weigh-ins and food diaries</p><p class="bulletIndent2"><span class="glyph">•</span>Active monitoring of physical activity and fitness levels</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients from the general population:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Use of multiple components (eg, diet, exercise, and behavioral therapy)</p><p class="bulletIndent2"><span class="glyph">•</span>Personalization</p><p class="bulletIndent2"><span class="glyph">•</span>More frequent contact</p><p class="bulletIndent2"><span class="glyph">•</span>Training for treatment providers</p><p></p><p class="headingAnchor" id="H120651351"><span class="h2">Preference for medication</span><span class="headingEndMark"> — </span>For most patients with SMI who are overweight and who seek treatment with medication to lose weight, we suggest first-line treatment with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> rather than other agents. <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a> or, in the case of patients treated with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, augmentation with <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> are reasonable alternatives, as well as <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a> if other options are not effective. An option for people who are gaining weight on <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> or are about to start olanzapine and wish to limit potential weight gain is the fixed-dose combination treatment olanzapine/samidorphan [<a href="#rid18">18</a>]. Each of these medications have demonstrated efficacy in this population in randomized controlled trials [<a href="#rid19">19-22</a>]. Clinical trials have not compared their efficacy among each other, but in our clinical experience, metformin is best tolerated and most effective. Topiramate and liraglutide may be more effective than aripiprazole but also more likely to cause side effects. The efficacy, side effects, dosing, and contraindications of these medications are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Adjunctive medications'</a>.)</p><p class="headingAnchor" id="H3553954457"><span class="h1">OTHER METABOLIC ABNORMALITIES</span><span class="headingEndMark"> — </span>Other metabolic abnormalities should be treated individually if they persist despite antipsychotic and lifestyle changes:</p><p class="headingAnchor" id="H3013482425"><span class="h2">Hyperglycemia/diabetes</span><span class="headingEndMark"> — </span>Mental health practitioners should feel confident in recognizing signs of hyperglycemia:</p><p class="bulletIndent1"><span class="glyph">●</span>Thirst</p><p class="bulletIndent1"><span class="glyph">●</span>Polyuria</p><p class="bulletIndent1"><span class="glyph">●</span>Weight loss</p><p class="bulletIndent1"><span class="glyph">●</span>Blurry vision</p><p></p><p>A recommended schedule for routine monitoring for hyperglycemia/diabetes in patients with severe mental illness (SMI) is shown in a table  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 1</a>) and reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Monitoring'</a>.)</p><p>Patients with new-onset diabetes (hemoglobin A1C &gt;6.5 percent, fasting blood glucose ≥126 mg/dL or random glucose ≥200 mg/dL) should be referred to a primary care clinician or endocrinologist for evaluation and treatment, but diabetes treatment may be possible in the mental health setting with primary care/internist consultation if there are no other options. (See <a class="local">'Site of treatment'</a> below.)</p><p>Initial management of type 2 diabetes is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1779.html" rel="external">"Initial management of hyperglycemia in adults with type 2 diabetes mellitus"</a>.)</p><p>The patient should also be referred to a lifestyle intervention developed for patients with SMI with diabetes, if available. If SMI-specific resources are not available, community-based resources that serve all patients with diabetes include diabetes self-management classes, nutrition, and physical activity programs. To enhance adherence to diabetes-care recommendations, we engage the patient's social supports and use motivational interviewing to set and monitor goals. We also involve peer support when available. Lifestyle interventions for patients with SMI with diabetes are reviewed separately, as is motivational interviewing (as applied to substance use disorders). (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Diabetes'</a> and  <a class="medical medical_review" href="/z/d/html/16752.html" rel="external">"Substance use disorders: Motivational interviewing"</a>.)</p><p class="headingAnchor" id="H2910105804"><span class="h2">Hypertension</span><span class="headingEndMark"> — </span>A recommended schedule for routine monitoring of blood pressure in patients with SMI is shown in a table  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 1</a>) and reviewed separately. Diagnosis of hypertension as well as selection and initiation of an antihypertensive agent are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Monitoring'</a> and  <a class="medical medical_review" href="/z/d/html/3852.html" rel="external">"Overview of hypertension in adults"</a>.)</p><p class="headingAnchor" id="H2649240174"><span class="h2">Dyslipidemia</span><span class="headingEndMark"> — </span>A recommended schedule for routine monitoring for dyslipidemia in patients with SMI is shown in a table  (<a class="graphic graphic_table graphicRef117454" href="/z/d/graphic/117454.html" rel="external">table 1</a>) and reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Monitoring'</a>.)</p><p>Management of dyslipidemia is reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/112841.html" rel="external">"Management of low density lipoprotein cholesterol (LDL-C) in the secondary prevention of cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H707223575"><span class="h1">TOBACCO SMOKING</span><span class="headingEndMark"> — </span>For patients with severe mental illness (SMI) attempting to stop smoking, we suggest first-line treatment with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) accompanied by smoking cessation education or a support group rather than other medication or psychosocial treatment. <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">Bupropion</a> is a reasonable alternative to varenicline if the latter is poorly tolerated or the patient continues to smoke after three months of treatment.</p><p>There is limited evidence comparing the efficacy of smoking cessation medications, but <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> appears to be more effective for smoking cessation compared with either NRT or <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> in patients with SMI. A clinical trial in 4116 SMI patients found that varenicline achieved greater abstinence compared with NRT (1.51, 95% CI 1.19-1.93), and compared with bupropion (1.41, 95% CI 1.11-1.79) over 24 weeks [<a href="#rid23">23</a>].</p><p>In patients with bipolar disorder and depression (or mood disorders), as well as schizophrenia (or other psychotic disorders), clinical trials have found <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> [<a href="#rid24">24-28</a>], <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> [<a href="#rid24">24,25,29,30</a>], and NRT [<a href="#rid24">24,31</a>] to be similarly efficacious as compared with placebo. An exception is that NRT has not been found to be efficacious in patients with schizophrenia/psychotic disorders [<a href="#rid30">30</a>], although this finding is confounded by a relatively small sample size. Earlier, smaller trials found inconsistent results for NRT, and for bupropion in bipolar disorder or depression (or mood disorders), but a large trial provided more robust evidence of efficacy [<a href="#rid30">30</a>].</p><p>The efficacy of smoking cessation medications in patients with SMI is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Tobacco smoking'</a>.)</p><p>In the general population, <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> [<a href="#rid32">32</a>], <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> sustained release [<a href="#rid33">33</a>], and NRT [<a href="#rid24">24,34,35</a>] are all efficacious for smoking cessation compared with placebo. The efficacy of smoking cessation medications in the general population is reviewed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/16635.html" rel="external">"Pharmacotherapy for smoking cessation in adults"</a>.)</p><p>Earlier concerns that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> might exacerbate symptoms of SMI were not borne out in subsequent, larger analyses [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Safety'</a>.)</p><p>Some data suggest that antidepressants can lead to improvement in negative symptoms of schizophrenia [<a href="#rid37">37</a>]. Antidepressants, including <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a>, can precipitate mania and must be used with caution in patients with bipolar disorder who are not also treated with a mood stabilizer. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults", section on 'Nicotine withdrawal'</a>.)</p><p>In addition to medication, we suggest adjunctive treatment with a cessation education or support group rather than a specific psychosocial intervention. In contrast to the general population, in which a number of psychosocial interventions have shown efficacy for smoking cessation, these treatments have not been shown to be efficacious in patients with SMI. (See  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a>.)</p><p>Among patients with SMI treated for smoking cessation, closer monitoring is warranted for those with more severe illness, suicidality, and/or unstable symptoms. Referral to or coordination with the patient's psychiatrist or other mental health provider is recommended.</p><p class="headingAnchor" id="H3671964764"><span class="h1">SITE OF TREATMENT</span><span class="headingEndMark"> — </span>For some patients with severe mental illness (SMI), the mental health care setting is their only site of clinical care. Some patients are unable or unwilling to follow through on a referral to primary care or attend regular visits for a chronic condition.</p><p>Given the risks of cardiovascular and other disease in patients with SMI and their impact on mortality, we often treat metabolic abnormalities (eg, by prescribing medications to treat hyperglycemia, hyperlipidemia, and/or hypertension). The provider’s level of comfort in doing so may be influenced by the presence of organizational support, or the availability of a primary care clinician or specialist for consultation [<a href="#rid38">38</a>].</p><p>In complex cases we consult a provider with expertise in treating metabolic abnormalities (eg, internal medicine, endocrinology). In many cases treatment is facilitated by a care manager or other allied health professional. Such personnel can also facilitate collaboration among clinicians, as well as patient navigation of often complex health care systems.</p><p class="headingAnchor" id="H2261636229"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109347.html" rel="external">"Society guideline links: Smoking cessation, e-cigarettes, and tobacco control"</a>.)</p><p class="headingAnchor" id="H1333183064"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to managing increased risk for cardiovascular disease in patients with severe mental illness (SMI) is summarized in an algorithm  (<a class="graphic graphic_algorithm graphicRef118498" href="/z/d/graphic/118498.html" rel="external">algorithm 1</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All overweight patients with SMI should receive education about nutrition and weight management and encouragement to increase physical activity. (See <a class="local">'Overview'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with antipsychotic-induced weight gain, the antipsychotic regimen should be reviewed for opportunities to reduce the dose and/or switch the antipsychotic from one with a higher risk of weight gain (eg, <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a>, <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">quetiapine</a>, <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">risperidone</a>) to one with a lower risk (eg, <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> or <a class="drug drug_general" data-topicid="10040" href="/z/d/drug information/10040.html" rel="external">ziprasidone</a>). Changes should be made slowly with careful monitoring to avoid an exacerbation of psychosis. (See <a class="local">'Patients taking an antipsychotic drug'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SMI with obesity or who are overweight, we favor first-line treatment for weight reduction with either a comprehensive lifestyle intervention or medication. The choice between them is based on their availability, as well as the patient’s preferences, motivation, and capabilities. (See <a class="local">'Obesity and overweight patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lifestyle interventions have been customized to address challenges faced by individuals with SMI. Other characteristics of lifestyle interventions associated with better outcomes are those with a longer duration, a manualized, structured approach, both health education and physical activity, and active monitoring. (See <a class="local">'Preference for lifestyle intervention'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For most patients with SMI with metabolic syndrome treated with medication to lose weight, we suggest first-line treatment with <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">metformin</a> rather than other medications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="10006" href="/z/d/drug information/10006.html" rel="external">Topiramate</a>, <a class="drug drug_general" data-topicid="9522" href="/z/d/drug information/9522.html" rel="external">liraglutide</a>, or, in the case of patients treated with <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">clozapine</a>, augmentation with <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">aripiprazole</a> are reasonable alternatives. For patients starting <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">olanzapine</a> or gaining weight on olanzapine, the combination treatment olanzapine/samidorphan can limit continued weight gain. (See <a class="local">'Preference for medication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SMI attempting to stop smoking, we suggest first-line treatment with <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9698" href="/z/d/drug information/9698.html" rel="external">nicotine</a> replacement therapy (NRT) rather than <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and NRT (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Bupropion is a reasonable alternative if the latter is poorly tolerated or if patient continues to smoke after three months’ treatment. (See <a class="local">'Tobacco smoking'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Earlier concerns that <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a> and <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> might exacerbate symptoms of SMI have not borne out in subsequent, more robust analyses. (See <a class="local">'Tobacco smoking'</a> above and  <a class="medical medical_review" href="/z/d/html/105342.html" rel="external">"Modifiable risk factors for cardiovascular disease in patients with severe mental illness", section on 'Safety'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SMI attempting to stop smoking, we suggest adjunctive treatment with a smoking cessation education or support group rather than a particular psychosocial intervention (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Tobacco smoking'</a> above and  <a class="medical medical_review" href="/z/d/html/6920.html" rel="external">"Behavioral approaches to smoking cessation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients who continue to smoke after taking <a class="drug drug_general" data-topicid="10339" href="/z/d/drug information/10339.html" rel="external">varenicline</a>/NRT for three months, we favor switching to <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">bupropion</a> and NRT rather than other medications. (See <a class="local">'Tobacco smoking'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with SMI with hyperglycemia, hyperlipidemia, and/or hypertension who are unwilling or unable to follow through on a referral to primary care, the psychiatrist should consider treating the conditions. Their ability to do so may be influenced by a level of comfort, the presence of organizational support, or the availability of a primary care clinician or specialist for consultation. (See <a class="local">'Site of treatment'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J 2005; 150:1115.</a></li><li><a class="nounderline abstract_t">Tiihonen J, Lönnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620.</a></li><li><a class="nounderline abstract_t">Laursen TM, Nordentoft M, Mortensen PB. Excess early mortality in schizophrenia. Annu Rev Clin Psychol 2014; 10:425.</a></li><li><a class="nounderline abstract_t">Bushe CJ, Taylor M, Haukka J. Mortality in schizophrenia: a measurable clinical endpoint. J Psychopharmacol 2010; 24:17.</a></li><li><a class="nounderline abstract_t">Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res 2000; 45:21.</a></li><li><a class="nounderline abstract_t">Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177:212.</a></li><li><a class="nounderline abstract_t">Daumit GL, Dickerson FB, Wang NY, et al. A behavioral weight-loss intervention in persons with serious mental illness. N Engl J Med 2013; 368:1594.</a></li><li><a class="nounderline abstract_t">Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66:1116.</a></li><li><a class="nounderline abstract_t">American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65:267.</a></li><li><a class="nounderline abstract_t">Baptista T, Kin NM, Beaulieu S, de Baptista EA. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives. Pharmacopsychiatry 2002; 35:205.</a></li><li><a class="nounderline abstract_t">Stroup TS, McEvoy JP, Ring KD, et al. A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). Am J Psychiatry 2011; 168:947.</a></li><li><a class="nounderline abstract_t">Brown S, Birtwistle J, Roe L, Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999; 29:697.</a></li><li><a class="nounderline abstract_t">McCreadie RG, Scottish Schizophrenia Lifestyle Group. Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 2003; 183:534.</a></li><li><a class="nounderline abstract_t">Strassnig M, Brar JS, Ganguli R. Nutritional assessment of patients with schizophrenia: a preliminary study. Schizophr Bull 2003; 29:393.</a></li><li><a class="nounderline abstract_t">Vandenberghe F, Gholam-Rezaee M, Saigí-Morgui N, et al. Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment. J Clin Psychiatry 2015; 76:e1417.</a></li><li><a class="nounderline abstract_t">Bonfioli E, Berti L, Goss C, et al. Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials. BMC Psychiatry 2012; 12:78.</a></li><li class="breakAll">Bartels S, Desilets R. Health Promotion Programs for People with Serious Mental Illness. SAMHSA-HRSA Center for Integrated Health Solutions; Department of Health and Human Services, Washington, DC 2012.</li><li><a class="nounderline abstract_t">Kahn RS, Kane JM, Correll CU, et al. Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study. J Clin Psychiatry 2023; 84.</a></li><li><a class="nounderline abstract_t">Mizuno Y, Suzuki T, Nakagawa A, et al. Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull 2014; 40:1385.</a></li><li><a class="nounderline abstract_t">Fiedorowicz JG, Miller DD, Bishop JR, et al. Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers. Curr Psychiatry Rev 2012; 8:25.</a></li><li><a class="nounderline abstract_t">Correll CU, Newcomer JW, Silverman B, et al. Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study. Am J Psychiatry 2020; 177:1168.</a></li><li><a class="nounderline abstract_t">Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2017; 74:719.</a></li><li><a class="nounderline abstract_t">Zawertailo L. Safety of smoking cessation drugs for mentally ill patients. Lancet 2016; 387:2481.</a></li><li><a class="nounderline abstract_t">Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet 2016; 387:2507.</a></li><li><a class="nounderline abstract_t">Tsoi DT, Porwal M, Webster AC. Interventions for smoking cessation and reduction in individuals with schizophrenia. Cochrane Database Syst Rev 2013; :CD007253.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Pratt SA, et al. Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial. JAMA 2014; 311:145.</a></li><li><a class="nounderline abstract_t">Chengappa KN, Perkins KA, Brar JS, et al. Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2014; 75:765.</a></li><li><a class="nounderline abstract_t">Anthenelli RM, Morris C, Ramey TS, et al. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial. Ann Intern Med 2013; 159:390.</a></li><li><a class="nounderline abstract_t">Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol 2007; 27:380.</a></li><li><a class="nounderline abstract_t">West R, Evins AE, Benowitz NL, et al. Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES. Addiction 2018; 113:1507.</a></li><li><a class="nounderline abstract_t">van der Meer RM, Willemsen MC, Smit F, Cuijpers P. Smoking cessation interventions for smokers with current or past depression. Cochrane Database Syst Rev 2013; :CD006102.</a></li><li><a class="nounderline abstract_t">Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev 2013; :CD009329.</a></li><li><a class="nounderline abstract_t">Hughes JR, Stead LF, Hartmann-Boyce J, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev 2014; :CD000031.</a></li><li><a class="nounderline abstract_t">Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002; 346:506.</a></li><li class="breakAll">Behavioral and Pharmacotherapy Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Women: U.S. Preventive Services Task Force Recommendation Statement. Available at: http://annals.org/article.aspx?articleid=2443060 (Accessed on October 28, 2015).</li><li class="breakAll">https://www.fda.gov/Drugs/DrugSafety/ucm532221.htm (Accessed on July 19, 2017).</li><li><a class="nounderline abstract_t">Helfer B, Samara MT, Huhn M, et al. Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis. Am J Psychiatry 2016; 173:876.</a></li><li><a class="nounderline abstract_t">Vanderlip ER, Raney LE, Druss BG. A Framework for Extending Psychiatrists' Roles in Treating General Health Conditions. Am J Psychiatry 2016; 173:658.</a></li></ol></div><div id="topicVersionRevision">Topic 117204 Version 13.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16338246" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Schizophrenia and increased risks of cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19595447" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24313570" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Excess early mortality in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20923917" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Mortality in schizophrenia: a measurable clinical endpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10978869" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Mortality and causes of death in schizophrenia in Stockholm county, Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11040880" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Causes of the excess mortality of schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23517118" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : A behavioral weight-loss intervention in persons with serious mental illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16187768" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15003083" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Consensus development conference on antipsychotic drugs and obesity and diabetes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12518268" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768610" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10405091" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : The unhealthy lifestyle of people with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14645025" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14552512" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Nutritional assessment of patients with schizophrenia: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26646038" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Importance of early weight changes to predict long-term weight gain during psychotropic drug treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22789023" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22789023" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Health promotion lifestyle interventions for weight management in psychosis: a systematic review and meta-analysis of randomised controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36946605" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Olanzapine/Samidorphan in Young Adults With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder Who Are Early in Their Illness: Results of the Randomized, Controlled ENLIGHTEN-Early Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636967" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22712004" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32791894" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28601891" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116919" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Safety of smoking cessation drugs for mentally ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27116918" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23450574" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Interventions for smoking cessation and reduction in individuals with schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24399553" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Maintenance treatment with varenicline for smoking cessation in patients with schizophrenia and bipolar disorder: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25006684" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Varenicline for smoking cessation in bipolar disorder: a randomized, double-blind, placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24042367" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17632223" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : A 12-week double-blind, placebo-controlled study of bupropion sr added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508470" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Factors associated with the efficacy of smoking cessation treatments and predictors of smoking abstinence in EAGLES.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23963776" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Smoking cessation interventions for smokers with current or past depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23728690" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Pharmacological interventions for smoking cessation: an overview and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24402784" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antidepressants for smoking cessation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844853" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Clinical practice. Treatment of tobacco use and dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844853" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical practice. Treatment of tobacco use and dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11844853" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical practice. Treatment of tobacco use and dependence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27282362" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Efficacy and Safety of Antidepressants Added to Antipsychotics for Schizophrenia: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27363548" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A Framework for Extending Psychiatrists' Roles in Treating General Health Conditions.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
